Generate Biomedicines, Inc. Common Stock (GENB) — Defensive Interval Ratio

Latest as of December 2025: 443 days

Generate Biomedicines, Inc. Common Stock (GENB) has a Defensive Interval Ratio of 443 days as of December 2025. Defensive assets of $99.85 Million (cash $-, short-term investments $99.85 Million, receivables $0.00) cover 443 days of daily cash needs of $225.21K/day. See Generate Biomedicines, Inc. Common Stock working capital to net assets to evaluate short-term liquidity relative to the company's equity base.

Defensive Interval Ratio

443 days
Days of operational coverage

Defensive Assets

$99.85 Million
Cash + ST Investments + Receivables

Daily Cash Need

$225.21K
Current Liabilities ÷ 365

Current Liabilities

$82.20 Million
USD

Generate Biomedicines, Inc. Common Stock Defensive Interval Ratio (2024–2025)

This chart shows how Generate Biomedicines, Inc. Common Stock's Defensive Interval Ratio has evolved across 2 annual periods from 2024 to 2025. As of December 2025, the ratio stands at 443 days, meaning defensive assets of $99.85 Million can fund 443 days of operations without new revenue. Also explore GENB net assets growth trend to track the company's year-over-year net asset growth rate.

Annual Defensive Interval Ratio for Generate Biomedicines, Inc. Common Stock (2024–2025)

The table below presents the year-by-year Defensive Interval Ratio for Generate Biomedicines, Inc. Common Stock from 2024 to 2025, covering 2 annual filings. Each row shows defensive assets, daily cash need, the DIR in days, and the change in days compared to the prior year. For live market cap and the full company financial profile, see how much is Generate Biomedicines, Inc. Common Stock worth.

Year DIR (days) Defensive Assets (USD) Daily Cash Need Cash ST Investments Change (days)
2025 443 days $99.85 Million $225.21K/day $- $99.85 Million ▼ -474 days
2024 917 days $217.67 Million $237.33K/day $- $217.36 Million
DIR = (Cash + Short-term Investments + Net Receivables) / (Daily Cash Expenses)